GIPR and type 2 diabetes mellitus: We did not observe a changed risk of T2D in LoFcAMP/LoFarr variant carriers in the UK Biobank, which is in contrast to the worsened insulin resistance and increased risk of T2D reported for the LoF-mimicking GIPR variant E354Q6,7.